Plenadren 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0043 
C.I.13 - Other variations not specifically covered 
28/09/2023 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
PSUSA/9176/
Periodic Safety Update EU Single assessment - 
22/06/2023 
22/06/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202211 
hydrocortisone (for centrally authorised products for 
the variation to terms of the Marketing Authorisation(s)’ for 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
adrenal insufficiency, congenital adrenal hyperplasia, 
PSUSA/9176/202211. 
modified-release formulations) 
IB/0041/G 
This was an application for a group of variations. 
13/01/2023 
n/a 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
IA/0040/G 
This was an application for a group of variations. 
12/12/2022 
n/a 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IAIN/0039/G 
This was an application for a group of variations. 
06/12/2022 
15/03/2023 
SmPC, Annex 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
II, Labelling 
and PL 
II/0038 
Update of section 4.4 of the SmPC in order to add a 
13/10/2022 
15/03/2023 
SmPC, Annex 
Pheochromocytoma crisis, which can be fatal, has been 
warning on pheochromocytoma crisis. The Package 
II, Labelling 
reported after administration of systemic corticosteroids. 
Leaflet is updated accordingly. In addition, the MAH 
and PL 
Corticosteroids should only be administered to patients with 
suspected or identified pheochromocytoma after an 
appropriate risk/benefit evaluation. 
took the opportunity to update the list of local 
representatives in the Package Leaflet and to 
implement other minor editorial corrections in the 
Annexes. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IAIN/0037 
B.II.b.2.c.1 - Change to importer, batch release 
14/03/2022 
15/03/2023 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0036 
Transfer of Marketing Authorisation 
21/12/2021 
20/01/2022 
SmPC, 
Labelling and 
PL 
IA/0035 
A.7 - Administrative change - Deletion of 
04/10/2021 
n/a 
manufacturing sites 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0033/G 
This was an application for a group of variations. 
05/02/2021 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/9176/
Periodic Safety Update EU Single assessment - 
11/06/2020 
n/a 
PRAC Recommendation - maintenance 
201911 
hydrocortisone (for centrally authorised products for 
adrenal insufficiency, congenital adrenal hyperplasia, 
modified-release formulations) 
IAIN/0031/G 
This was an application for a group of variations. 
14/08/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
IA/0030/G 
This was an application for a group of variations. 
19/12/2018 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
IA/0029 
B.II.d.2.a - Change in test procedure for the finished 
28/06/2018 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0028/G 
This was an application for a group of variations. 
15/05/2018 
31/01/2019 
SmPC, 
B.II.e.5.b - Change in pack size of the finished 
product - Deletion of a pack size(s) 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IAIN/0027/G 
This was an application for a group of variations. 
27/02/2018 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Primary packaging 
site 
IAIN/0026 
B.II.b.2.c.1 - Change to importer, batch release 
16/02/2018 
31/01/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0024 
Submission of an updated RMP (version 3.1) in order 
26/10/2017 
n/a 
to submit protocol amendments of the SHP 617-400 
(EU-AIR) study – A European multicentre, multi-
country, post-authorisation, observation study 
(registry) of patients with chronic adrenal 
insufficiency (category 3); additionally, the 
opportunity is being taken to implement a change 
agreed by the PRAC/CHMP as part of the assessment 
of MEA 005.3 in July 2016 and remove from the RMP 
the reference to study SHP617-404 (SWE-DUS), a 
Category 3 study to monitor off-label use of 
Plenadren to evaluate physician prescribing patterns. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/9176/
Periodic Safety Update EU Single assessment - 
09/06/2017 
n/a 
PRAC Recommendation - maintenance 
201611 
hydrocortisone (for centrally authorised products for 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
adrenal insufficiency, congenital adrenal hyperplasia, 
modified-release formulations) 
IA/0025 
B.II.b.2.a - Change to importer, batch release 
07/04/2017 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
II/0022 
To update the SmPC section 4.8 (Undesirable 
13/10/2016 
21/09/2017 
SmPC and PL 
Effects) and PIL section 4 (Possible side effects) of 
the Plenadren 5mg and 20 mg (hydrocortisone) 
modified release tablets. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
R/0020 
Renewal of the marketing authorisation. 
23/06/2016 
08/08/2016 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Plenadren in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
II/0021 
Update of sections 4.4 and 4.8 of the SmPC in order 
26/05/2016 
08/08/2016 
SmPC and PL 
In this variation the MAH has included information on acute 
to add acute adrenocortical insufficiency as a new 
ADR based on post marketing experience and to 
include a relevant warning towards alignment with 
the Company Core Data Sheet. The Package Leaflet 
is updated in accordance. In addition, section 4.2 has 
been updated to replace parenteral administration of 
hydrocortisone with intravenous administration in 
line with currently published guidelines. Moreover, 
adrenal insufficiency in the Product Information to explain 
that the acute adrenal insufficiency may develop in patients 
with known adrenal insufficiency who are on inadequate 
daily doses or in situations with increased cortisol need. 
Events have been reported in patients treated with 
Plenadren. Adrenal crisis can develop in patients with acute 
adrenal insufficiency. Therefore, patients should be advised 
of the signs and symptoms of acute adrenal insufficiency 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
the Marketing authorisation holder (MAH) took the 
opportunity to make minor editorial changes in the 
SmPC and Package Leaflet. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
and of adrenal crisis and the need to seek immediate 
medical attention. During acute adrenal crisis parenteral, 
preferably intravenous administration of hydrocortisone in 
high doses, together with sodium chloride 9 mg/ml (0.9%) 
solution for infusion, should be administered according to 
current treatment guidelines. 
PSUSA/9176/
Periodic Safety Update EU Single assessment - 
13/05/2016 
n/a 
PRAC Recommendation - maintenance 
201511 
hydrocortisone (for centrally authorised products for 
adrenal insufficiency, congenital adrenal hyperplasia, 
modified-release formulations) 
IA/0019 
B.I.b.1.b - Change in the specification parameters 
29/02/2016 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
IG/0603/G 
This was an application for a group of variations. 
03/12/2015 
11/05/2016 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
II, Labelling 
and PL 
IG/0621 
C.I.8.a - Introduction of or changes to a summary of 
16/10/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/9176/
Periodic Safety Update EU Single assessment - 
07/05/2015 
n/a 
PRAC Recommendation - maintenance 
201411 
hydrocortisone (for centrally authorised products for 
adrenal insufficiency, congenital adrenal hyperplasia, 
modified-release formulations) 
PSUV/0013 
Periodic Safety Update 
10/07/2014 
n/a 
PRAC Recommendation - maintenance 
IAIN/0014 
C.I.8.a - Introduction of or changes to a summary of 
02/07/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0012/G 
This was an application for a group of variations. 
05/02/2014 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV and/or QPPV contact details and/or back-up 
procedure 
C.I.9.b - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change(s) in the 
safety database and/or major contractual 
arrangements for the fulfilment of PhV obligations, 
and/or change of the site undergoing PhV activities 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the PhV system 
IB/0011/G 
This was an application for a group of variations. 
10/07/2013 
20/11/2013 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
Labelling and 
PL 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IA/0010 
B.II.c.1.c - Change in the specification parameters 
13/05/2013 
n/a 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IAIN/0009/G 
This was an application for a group of variations. 
17/04/2013 
n/a 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IAIN/0008 
B.II.b.2.b.1 - Change to batch release arrangements 
07/11/2012 
20/11/2013 
Annex II and 
and quality control testing of the FP - Not including 
PL 
batch control/testing 
IA/0007/G 
This was an application for a group of variations. 
24/10/2012 
n/a 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
Monograph - Updated certificate from an already 
approved manufacturer 
IAIN/0005 
C.I.9.i - Changes to an existing pharmacovigilance 
13/09/2012 
n/a 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
relation to another medicinal product of the same 
MAH 
IB/0004 
C.I.8.b - Introduction of a new Pharmacovigilance 
13/08/2012 
n/a 
system - which has been assessed by the relevant 
NCA/EMA for another product of the same MAH 
IB/0002 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
24/05/2012 
29/10/2012 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
T/0001 
Transfer of Marketing Authorisation 
10/02/2012 
26/03/2012 
SmPC, 
Labelling and 
PL 
Page 12/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
